CD38 and plasma cell myeloma: Daratumumab, anti-CD38 mAb approved for the treatment of multiple myeloma, showed anti-leukemic effects in combination with ponatinib in R/R Ph+ ALL in a single case study [166] and is further investigated in a clinical trial in pediatric and young adult R/R B-ALL (NCT03384654).